The first comprehensive analysis of three major lung diseases, asthma, chronic obstructive pulmonary disease (COPD), and interstitial lung disease (ILD), across England, Wales, Scotland, and Northern Ireland has been published.
Michael Roth discusses soluble circulating cytokine receptors in chronic inflammatory lung diseases, which he describes as the under-estimated regulators of inflammation and remodelling.
According to Maximilian Kunisch and Giuseppe De Carlo from the European Federation of Allergies and Airways Diseases Patients' Associations, respiratory patients in Europe need to set the research priorities for asthma and chronic obstructive pulmonary disease (COPD).
The work of the Centers for Disease Control and Prevention, within the U.S. Department of Health & Human Services is examined here, with a special focus on traumatic brain injury.
Dr Fred A. Wagshul, Pulmonologist and Medical Director at the Lung Center of America explains why he supports the addition of asthma medications to the exemption list in the UK.
Paul Riddick, Co-Founder and Technical Director at Vodex explores how contaminates being produced on a daily basis in the workplace can damage your health and could even prove fatal.
Michael Roth, Research Group Leader at University Hospital Basel asks if disturbed cell-cell interaction causes asthma and provides a fascinating response.
Asthma UK’s recent report reveals the debilitating impact asthma prescription charges are having on people’s health and wellbeing. Dr Samantha Walker, Director of Policy and Research at Asthma UK explains more.
Michael Roth, Research Group Leader at the University Hospital Basel explains what asthma is, its health impact and charts research landscape in the field.
Michael Roth, Research Group Leader at the University Hospital Basel & University Basel share his expertise on asthma and COPD, the most prevalent chronic inflammatory diseases of the lung globally
Asthma UK’s recent report explores the barriers to life-changing treatment for people with uncontrolled asthma, as Joe Farrington-Douglas, Head of Policy and External Affairs at Asthma UK explains.
Katy Beckford and Alex Christie from the Association of Respiratory Nurse Specialists detail precisely why dyspnoea (breathlessness) remains an ongoing battle today
